Abstract Purpose of Review [177Lu] Lu-PSMA-617 is a radiopharmaceutical that emits beta-
minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate …

Introduction The prostate-specific membrane antigen (PSMA) targeted radioligand therapy
(PRLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients …

Metastatic prostate cancer continues to be an incurable disease. Despite all the novel
therapies approved in the past two decades, overall patient outcomes remain relatively poor …

Radiopharmaceuticals have been utilized for men with advanced prostate cancer for
decades. Older agents, seldom used today, provided palliation for bone metastatic pain. In …

Introduction Radio-ligand targeted therapy is a new and promising concept of treatment
Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were …

177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …

Simple Summary The risk of prostate cancer development, the second most commonly
occurring cancer in men overall, increases strongly with age. About 10% of patients …

PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …

Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …

Metastatic castration‐resistant prostate cancer (mCRPC) remains a challenging condition to
treat despite recent advancements. This retrospective study aimed to assess the activity and …